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ABSTRACT 
 
Background: Type 1 diabetes mellitus (T1DM) is a polygenic disease caused by multiple susceptibility and 
protective alleles interacting with each other. However, studies showed that the genes responsible for more than 
50% of the genetic predisposition to T1DM, are located in the human leukocyte antigen (HLA) region on 
chromosome 6. Out of all three HLA classes, the HLA class II loci DQA1, DQB1 and DRB1 contribute most to the 
genetic predisposition to T1DM. This study determines the HLA-DRB1 allele association with susceptibility and 
protection to T1DM in Egyptian children. Results: The study is a HLA-Class II-DRB1 allele typing, which was 
carried out with polymerase chain reaction -sequence specific primer. It was conducted on 61 unrelated Egyptian 
children with T1DM, and 19 unrelated age- and sex- matched healthy subjects. Results of the HLA typing confirmed 
a positive association of the following alleles with T1DM; DRB1*03:01:01:01, DRB1*03:01:06, DRB1*03:01:12, 
DRB1*03:01:16, DRB1*03:07, DRB1*03:08, DRB1*03:10, DRB1*03:12, DRB1*03:42, DRB1*03:76, 
DRB1*03:86, DRB1*08:17, DRB1*11:07, DRB1*11:08:01, DRB1*11:23, DRB1*11:36, DRB1*11:67, 
DRB1*12:12, DRB1*13:144, DRB1*13:154, DRB1*13:18, DRB1*13:119, DRB1*13:146 and DRB1*15:21. On 
the other hand, protection against T1DM was conferred by the HLA DRB1*01:03, DRB1*13:45, DRB1*14:04, 
DRB1*14:31 and DRB1*15:62 alleles. Conclusion: Increased frequencies of certain HLA-DRB1 alleles, known to 
be positively associated with T1DM, which are consistent with other studies. In addition to the well known alleles, 
our study confirmed the association of some other alleles that might be unique for Egyptians. However, the 
protective effect of previously reported alleles was not confirmed, instead other HLA-DRB1 alleles are now in 
question. 
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Introduction 
 
Diabetes mellitus is considered as one of the most 
rapidly growing diseases worldwide. The International 
Diabetes Federation estimated in 2011 that 366 million 
people worldwide suffered from diabetes, which is 
expected to increase to 552 million people by the year 
2030. [1] T1DM is most commonly an autoimmune 
disease that results from the destruction of insulin 
secreting beta cells of the islets of Langerhans by auto-
reactive T-lymphocytes. [2] It is a clear example of a 
complex multi-factorial disease resulting from the 
interaction of several environmental as well as genetic 
factors. [3]   Both genome screens and studies led to the 
conclusion that T1DM is a genetically polygenic 
disease caused by multiple susceptibility and protective 
alleles interacting with each other. [4] 
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Before the extraordinary success of the Genome-wide 
association studies (GWAS) only six susceptibility 
genes were discovered. However, GWAS resulted in 
the identification of a number of new genes associated 
with T1DM, reaching 60 genes in 2012. [5] Studies 
showed that the most important genes, responsible for 
more than 50% of the genetic predisposition to T1DM, 
are located in the HLA region on chromosome 6. [6] 
This region consists of a total of 224 genes, arranged in 
separate clusters forming three different classes: class 
I, class II and class III. [7] Even though HLA class I 
was found to be associated with T1DM, the HLA class 
II loci DQA1, DQB1 and DRB1 contribute most to the 
genetic predisposition to T1DM. [8] However, the risk 
caused by certain HLA alleles as well as the protection 
obtained from other alleles varies across different 
ethnical groups and geographical regions. [9]Egypt is 
considered as one of the developing countries in the 
Middle -East with the highest rates of diabetes. [10] A 
study performed on the Egyptian population suggests 
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that the number of diagnosed and undiagnosed people 
with diabetes will reach 8.80 million by the year 2025. 
[11] This high prevalence rate makes the study of the 
HLA genotype in the Egyptian population necessary. 
[12]This study was designed to determine HLA-DRB1 
allele association with the susceptibility and/or 
protection to T1DM in a random group of Egyptian 
children.  
Materials and methods 
 
Subjects 
 
This study was conducted on 61 unrelated Egyptian 
children diagnosed with T1DM. They were presented 
to the pediatric inpatient’s wards of the National 
Institute for Diabetes and Endocrinology, El 
KasrEleiny, Cairo, Egypt. The study included 32 males 
and 28 females. The mean age of the patients is 11.87± 
0.48.The control group involved 19 unrelated age- and 
sex-matched healthy subjects without T1DM or any 
other autoimmune disease. After the protocol was 
approved by the local ethical committee, written 
consents were obtained from the parents of the patients 
and controls. 
 
HLA class II- DRB1 allele typing 
 
Genomic DNA extraction was done for all samples 
using a DNA purification kit (PureLink® Genomic 
DNA mini Kit Cat. K1820-01, Lot No. 1398040, 
Invitrogen,Life technologies). HLA Class II-DRB1 
allele typing was carried out with a polymerase chain 
reaction-sequence-specific primer using MICRO 
SSP™ HLA DNA typing trays (Lot number #004, One 
Lambda, Inc.). Test conditions were according to the 
manufacturer’s instructions.  
 
Statistical analysis 
 
All statistical calculations were done using SPSS 
(Statistical Package for the Social Science; SPSS Inc., 
Chicago, IL, USA) version 21. Data was statistically 
described in terms of frequencies and percentages for 
qualitative data. For comparing categorical data, Fisher 
Exact test was used. Genotype and allele frequencies 
were compared between the disease and the control 
groups using Fisher exact test. Odds ratio (OR) with 
95% confidence intervals was calculated. A probability 
value (P value) less than 0.05 was considered 
statistically significant.  
 
Results 
 
Characteristics of the Participants:                                                                      
 By comparing the data obtained from the patients and 
controls, it was obvious that the patients had elevated 
fasting blood glucose levels (247.58± 13 vs. 80.68± 
1.37mmol/litre; P < 0.001) and glycated hemoglobin ( 
HbA1c) levels (10.84±0.21 vs. 5.26±0.05 as a percent 
of total hemoglobin; P < 0.001). The kidney and liver 
functions however, didn’t show any significant 
difference between patients and controls. 
 
Frequencies of HLA-DRB1 alleles: 
 
The HLA-DRB1 allele frequencies found in 61 T1DM 
patients and 19 healthy controls are given in Table 1. 
Significant differences were detected between T1DM 
patients and controls in the frequencies of 
DRB1*03:01:01(85.2% vs. 36.6%, P <0.001), 
DRB1*03:01:06 (65.6% vs. 5.3%, P < 0.001), 
DRB1*03:01:12 (85.2% vs. 36.6%, P <0.001), 
DRB1*03:01:16 (77.0% vs. 31.6%, P = 0.001), 
DRB1*03:07 (83.6% vs. 36.8%, P < 0.001), 
DRB1*03:08 (70.5% vs. 15.8%, P < 0.001),  
DRB1*03:42 (83.6% vs. 31.6%, P < 0.001), 
DRB1*03:76 (75.4% vs. 26.3%, P < 0.001), 
DRB1*03:86 (73.8% vs. 15.8%, P < 0.001), 
DRB1*08:17 (72.1% vs. 10.5%,  P < 0.001), 
DRB1*11:07 (72.1% vs. 21.1%, P < 0.001), DRB1* 
11:08:01 (68.9% vs. 15.8%, P < 0.001), DRB1*11:23 
(82.0% vs. 36.8, P < 0.001) DRB1*11:36 (83.6% vs. 
36.8, P < 0.001), DRB1*11:67 (73.8% vs. 21.1%, P < 
0.001), DRB1*12:12 (68.9% vs. 10.5%, P < 0.001), 
DRB1*13:119 (86.9% vs. 31.6%, P < 0.001) and 
DRB1*15:21 (67.2% vs. 15.8%, P < 0.001). In 
addition, the allelic frequencies DRB1*03:10 (86.9% 
vs. 57.9%, P 0.017), DRB1*03:12 (86.9% vs. 47.4%, P 
0.001), DRB1*13:144 (90.2% vs. 57.9%, P0.003), 
DRB1*13:154 (86.9% vs. 63.2%, P0.039), 
DRB1*13:18 (90.2% vs. 57.9%, P0.003) and 
DRB1*13:71 (86.9% vs. 47.4%, P0.001) showed also  
significant differences between patients and controls. 
 On the other hand, the alleles DRB1*01:03(31.6% vs. 
3.3%, P0.002), DRB1*13:45(89.5% vs. 63.9%, P = 
0,045), DRB1*14:04 (36.8% vs. 11.5%, P0.018), 
DRB1*14:31 (36.8% vs. 8.2%, P 0.006) and 
DRB1*15:62 (36.8% vs. 8.2%, P0.006) were found 
significantly higher in controls than in patients. 
Differences in the frequencies of other DRB1 alleles 
between patients and controls were insignificant. 
(Table 1) 
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Table 1: Significant HLA-DRB1 allele frequencies in patients and controls 
 
 
Patients(61) Control (19) P-value OR 95% CI 
DRB1*03:01:01:01 52 85.2% 6 31.6% < 0.001 12.519 3.776-41.501 
DRB1*03:01:06 40 65.6% 1 5.3% < 0.001 34.286 4.276-274.930 
DRB1*03:01:12 52 85.2% 6 31.6% < 0.001 12.519 3.776-41.501 
DRB1*03:01:16 47 77.0% 6 31.6% 0.001 7.274 2.334-22.666 
DRB1*03:07               51 83.6% 7 36.8% < 0.001 8.743 2.761-27.682 
DRB1*03:08 43 70.5% 3 15.8% < 0.001 12.741 3.302-49.162 
DRB1*03:10 53 86.9% 11 57.9% 0.017 4.818 1.487-15.612 
DRB1*03:12 53 86.9% 9 47.4% 0.001 7.361 2.290-23.664 
DRB1*03:42 51 83.6% 6 31.6% < 0.001 11.050 3.391-36.004 
DRB1*03:76 46 75.4% 5 26.3% < 0.001 8.587 2.650-27.825 
DRB1*03:86 45 73.8% 3 15.8% < 0.001 15.000 3.855-58.366 
DRB1*08:17 44 72.1% 2 10.5% < 0.001 22.000 4.584-105.580 
DRB1*11:07 44 72.1% 4 21.1% < 0.001 9.706 2.818-33.433 
DRB1*11:08:01 42 68.9% 3 15.8% < 0.001 11.789 3.066-45.338 
DRB1*11:23 50 82.0% 7 36.8% < 0.001 7.792 2.497-24.315 
DRB1*11:36 51 83.6% 7 36.8% < 0.001 8.743 2.761-27.682 
DRB1*11:67 45 73.8% 4 21.1% < 0.001 10.547 3.047-36.509 
DRB1*12:12 42 68.9% 2 10.5% < 0.001 18.789 3.940-89.609 
DRB1*13:119 53 86.9% 6 31.6% < 0.001 14.354 4.238-48.620 
DRB1*13:144 55 90.2% 11 57.9% 0.003 6.667 1.928-23.055 
DRB1*13:146 55 90.2% 12 63.2% 0.01 5.347 1.522-18.787 
DRB1*13:154 53 86.9% 12 63.2% 0.039 3.865 1.173-12.732 
DRB1*13:18 55 90.2% 11 57.9% 0.003 6.667 1.928-23.055 
DRB1*13:45 39 63.9% 17 89.5% 0.045 0.209 0.044-0.988 
DRB1*13:71 53 86.9% 9 47.4% 0.001 7.361 2.29-23.664 
DRB1*14:04 7 11.5% 7 36.8% 0.018 0.222 0.066-0.753 
DRB1*14.31 5 8.2% 7 36.8% 0.006 0.153 0.041-0.565 
DRB1*15.21 41 67.2% 3 15.8% < 0.001 10.933 2.851-41.922 
DRB1*15:62 5 8.2% 7 36.8% 0.006 0.153 0.041-0.565 
 
Discussion 
 
The incidence of T1DM is increasing rapidly 
throughout the world with a rate that is highly variable 
among different ethnic groups. [13]Egypt is a country 
located in North Africa between the Mediterranean 
world, the Arab world and Black Africa. As a result of 
this special location the genetic components of the 
Egyptian population is somehow a combination of 
Arabs, Bedouins and to a small extent Berber. 
Therefore Egyptians are classified between Caucasians 
and Africans. However they are considered to be closer 
to Caucasians. [14]Studies proved that HLA-DR-DQ 
represent about 40-50% of the disease susceptibility. 
[8]Different population-based association studies have 
shown a strong relationship between HLA-DR3 and -
DR4 and T1DM in Caucasoid populations. 
[13]Analysis of the frequencies of the HLA-DRB1 
alleles in our patients compared to the control group 
revealed that DRB1*03:01:01:01, *03:01:06, *03:01:12 
and *03:01:16 were positively associated with T1DM 
(P < 0.001, P < 0.001, P < 0.001 and P = 0.001 
respectively). These observations are consistent with 
the findings in previous studies conducted on different 
Caucasoid and Arab populations which showed a 
strong disease association with the DRB1*03:01 alleles. 
These studies included the study of Benseffaj on the 
Moroccan population [15], the Bahraini study of Al-
Harbi et al. [16] as well as the Slovakian study by Buc 
et al. [9].In addition to the well known DRB1*03:01 
alleles our patients showed a strong association 
between other DRB1*03 alleles and T1D; such as 
DRB1*03:07 (P < 0.001), DRB1*03:08 (P < 0.001), 
DRB1*03:10 (P = 0.017), DRB1*03:12 (P =0.001), 
DRB1*03:42(P < 0.001), DRB1*03:76 (P < 0.001) and 
DRB1*03:86 (P < 0.001).Our study however, didn’t 
reveal any association of DR4 alleles. Although there 
seemed to be a difference between patients and 
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controls, yet this difference was not clinically 
significant (P = 0.054). A previous study done on the 
Egyptian population in 2011 also showed an 
insignificant difference between diabetic patients and 
controls for DRB1*04 subtypes. [17] This was also the 
case in the Romanian study carried on by Durbală in 
2009. [18] Two Lebanese studies also showed a strong 
association for DR3 alleles with no significant 
association for DR4 alleles. [19, 20]. Nevertheless, a 
larger study must be done in order to be able to 
investigate the predisposing effect of HLA-DR4 alleles 
on the Egyptian population. Furthermore our study 
exposed the predisposing role of a number of other 
genesincluding,DRB1*08:17(P<0.001),DRB1*11:07(P 
< 0.001), DRB1*11:08:01(P < 0.001), DRB1*11:23(P 
< 0.001), DRB1*11:36 (P < 0.001), DRB1*11:67 (P < 
0.001), DRB1*12:12 (P < 0.001), DRB1*13:119 (P < 
0.001), DRB1*13:144 (P = 0.003), DRB1*13:146 (P = 
0.01), DRB1*13:154 (P = 0.039), DRB1*13:18 (P = 
0.003), DRB1*13:71(P = 0.001) and DRB1*15:21 (P < 
0.001). Interestingly, the number of alleles thought to 
be involved with T1DM in the Egyptian population in 
this study is numerous. However, when taking in 
consideration the fact that Egypt is considered as one 
of the countries with highest rates of diabetes, the 
extremely high numbers of predisposing alleles might 
be explained. On the other hand, a negative association 
to T1DM was reported with the following DRB1 
alleles: DRB1*01:03, DRB1*13:45, DRB1*14:04, 
DRB1*14:31 and DRB1*15:62 (P = 0.002, P = 0.045, 
P = 0.018, P = 0.006 and P = 0.006 respectively). 
Although these results were not expected, since 
previous population-based studies carried on 
Caucasians and Arabs, usually showed DRB1*11:01 
and DRB1*15:01. In addition a former study 
performed on the Egyptian population also revealed 
DRB1*11:01, DRB1*10:01 and DRB1:15:01 to play a 
protective role against T1DM [17], unlike our study, 
which did not show a significant difference between 
controls and patients for these alleles. However a few 
studies proved DR13 as well as DR14 sub-alleles to 
have a protective role. One of these studies were 
conducted on Saudi patients [21] and showed a 
significant negative association between T1DM and 
DRB1*13:07. Another study from Turkey [13] also 
revealed the T1DM-protective effect of DRB1*13:01 
and DRB1*14:01 alleles. The Bahraini population as 
well showed in a study a strong negative association 
between DRB1*13:07:01 and T1DM [16].According to 
the results of this study, we can conclude that the 
Egyptian population showed some similarities with 
other populations regarding the alleles known to be 
positively associated with T1DM. However, the study 
reported some alleles that might be unique for Egyptian 
children. On the other hand, the previously reported 
alleles with known protective effect were not reported 
in this study. 
Last but not least further studies on large scales are 
required for a more precise understanding of the HLA 
genotype in the Egyptian population. 
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